Tandem Diabetes Care, Inc.

Equities

TNDM

US8753722037

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-28 EDT			5-day change	1st Jan Change
40.29 ^USD	-0.35%		-5.95%	+36.21%

06-20	Tandem Diabetes Care Names Jean-Claude Kyrillos COO	MT
06-20	Tandem Diabetes Care, Inc. Appoints Jean-Claude Kyrillos as Executive Vice President and Chief Operating Officer, Effective June 21, 2024	CI

Tandem Diabetes Care, Inc. Reports Preliminary Unaudited Sales for the Fourth Quarter and Full Year Ended December 31, 2022

January 10, 2023 at 04:05 pm

Tandem Diabetes Care, Inc. reported preliminary Unaudited sales for the fourth quarter and full year ended December 31, 2022. For the quarter, the company expects GAAP sales increased to approximately $221 million from $210 million.
For the year ended December 31, 2022, the company expects GAAP sales increased to approximately $802 million from $703 million.

Latest news about Tandem Diabetes Care, Inc.

Tandem Diabetes Care Names Jean-Claude Kyrillos COO	06-20	MT
Tandem Diabetes Care, Inc. Appoints Jean-Claude Kyrillos as Executive Vice President and Chief Operating Officer, Effective June 21, 2024	06-20	CI
Tandem Diabetes Care, Inc. and Dexcom, Inc. Enter into Amended and Restated Development Agreement to Original Development Agreement and Amended and Restated Commercialization Agreement to Original Commercialization Agreement	06-18	CI
Oppenheimer Adjusts Price Target on Tandem Diabetes Care to $58 From $47, Maintains Outperform Rating	06-10	MT
Transcript : Tandem Diabetes Care, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 08:00 AM	06-06
Tandem Diabetes Care Insider Sold Shares Worth $258,400, According to a Recent SEC Filing	06-03	MT
Redburn Atlantic Starts Tandem Diabetes Care With Buy Rating, $60 Price Target	05-30	MT
Transcript : Tandem Diabetes Care, Inc. Presents at 2024 Leerink Partners Healthcare Crossroads Conference, May-29-2024 11:20 AM	05-29
Lake Street Adjusts Price Target on Tandem Diabetes Care to $75 From $60, Maintains Buy Rating	05-22	MT
Stifel Adjusts Price Target on Tandem Diabetes Care to $55 From $45, Maintains Buy Rating	05-22	MT
Citi Upgrades Tandem Diabetes Care to Buy, Price Target at $57	05-22	MT
Social Buzz: Wallstreetbets Stocks Mostly Lower Premarket Wednesday; Hims & Hers Health, Tesla to Decline	05-22	MT
Tandem Diabetes Care, Inc. and Unomedical a/s Enter into Amendment Number 1 to Distributor Agreement	05-16	CI
Transcript : Tandem Diabetes Care, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:00 AM	05-15
Sector Update: Health Care Stocks Mixed in Afternoon Trading	05-03	MT
Tandem Diabetes Care Shares Rise After Q1 Net Loss Shrinks, Sales Rise; Q2, 2024 Sales Guidance Set	05-03	MT
UBS Adjusts Price Target on Tandem Diabetes Care to $40 From $28, Maintains Neutral Rating	05-03	MT
Transcript : Tandem Diabetes Care, Inc., Q1 2024 Earnings Call, May 02, 2024	05-02
Earnings Flash (TNDM) TANDEM DIABETES CARE Reports Q1 Revenue $191.7M, vs. Street Est of $173.5M	05-02	MT
Tandem Diabetes Care, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
North American Morning Briefing : More Earnings -2-	04-30	DJ
Wells Fargo Upgrades Tandem Diabetes Care to Overweight From Equalweight, Price Target is $45	04-29	MT
North American Morning Briefing : Tech Still in -2-	04-26	DJ
Leerink Partners Upgrades Tandem Diabetes Care to Outperform Rating, Price Target is $45	04-25	MT
Stifel Adjusts Price Target on Tandem Diabetes Care to $40 From $37, Maintains Buy Rating	04-23	MT

Chart Tandem Diabetes Care, Inc.

Duration

Period

More charts

Company Profile

Tandem Diabetes Care, Inc. is a global insulin delivery and diabetes technology company, which manufactures and sells advanced automated insulin delivery systems. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of it AID systems, it offers pump integration with multiple CGM sensors.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-07-31 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Tandem Diabetes Care, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

40.43 USD

Average target price

49.93 USD

Spread / Average Target

+23.51%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
TANDEM DIABETES CARE, INC.	+36.21%	2.61B
ABBOTT LABORATORIES	-5.60%	182B
MEDTRONIC PLC	-4.45%	102B
BECTON, DICKINSON AND COMPANY	-4.15%	66.74B
DEXCOM, INC.	-8.63%	45.55B
CENCORA, INC.	+9.70%	44.89B
HOYA CORPORATION	+6.13%	40.62B
METTLER-TOLEDO INTERNATIONAL, INC.	+15.22%	30.04B
TERUMO CORPORATION	+14.80%	24.34B
WEST PHARMACEUTICAL SERVICES, INC.	-6.46%	23.95B

Other Medical Equipment, Supplies & Distribution